The Filing Desk

ANI Pharmaceuticals vs Madrigal Pharmaceuticals

ANI Pharmaceuticals ANIP · Madrigal Pharmaceuticals MDGL · Pharmaceuticals

Madrigal Pharmaceuticals reported revenue of $958 million in fiscal 2025, about the same as ANI Pharmaceuticals' $883 million in fiscal 2025. ANI Pharmaceuticals' revenue grew 43.8% in its latest year, and Madrigal Pharmaceuticals' grew 432.1%. ANI Pharmaceuticals had an operating margin of 12.6%, against -31.3% at Madrigal Pharmaceuticals. Free cash flow was $171 million at ANI Pharmaceuticals and −$190 million at Madrigal Pharmaceuticals.

Side by side

ANI PharmaceuticalsMadrigal Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$883M$958M
Revenue growth43.8%432.1%
Revenue growth a year, last 5 years33.5%—
Gross margin——
Operating margin12.6%−31.3%
Net margin8.9%−30.1%
Free cash flow$171M−$190M
Free cash flow margin19.4%−19.8%
Return on capital15.9%—
Net debt to EBITDA0.1x—
Dividends and buybacks$13M$0M
Change in diluted share count9.9%5.5%
Last close$69.13$396.74
P/E at the last close13.8×—
Insider trades, last 12 monthssold $13.6 millionsold $69.0 million
Piotroski F-score6 of 83 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ANI PharmaceuticalsMadrigal Pharmaceuticals
Operating margin
Percent of revenue
ANI PharmaceuticalsMadrigal Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ANI PharmaceuticalsMadrigal Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ANI Pharmaceuticals and Madrigal Pharmaceuticals pages.